Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.

Autor: Righi S; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 11, 40138 Bologna, Italy. Electronic address: simona.righi5@unibo.it., Novero D; Unit of Surgical Pathology - University Hospital of Turin, Città Della Salute - Ospedale Le Molinette, Corso Bramante 88, 10126, Turin, Italy. Electronic address: domenico.novero@gmail.com., Godio L; Unit of Surgical Pathology - University Hospital of Turin, Città Della Salute - Ospedale Le Molinette, Corso Bramante 88, 10126, Turin, Italy. Electronic address: lgodio@cittadellasalute.to.it., Bertuzzi C; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address: claraberuzzi@gmail.com., Bacci F; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address: francesco.bacci@aosp.bo.it., Agostinelli C; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 11, 40138 Bologna, Italy. Electronic address: claudio.agostinelli@unibo.it., Sagramoso C; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address: carloalberto.sagramososacchetti@aosp.bo.it., Rossi M; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Massarenti 11, 40138 Bologna, Italy. Electronic address: maura.rossi3@unibo.it., Piccioli M; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address: milena.piccioli@aosp.bo.it., Gazzola A; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address: anna.gazzola@aosp.bo.it., Mannu C; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address: claudia.mannu@aosp.bo.it., Roncador G; Biotechnology Program, Spanish National Cancer Research Centre, C/ Melchor Fernández Almagro 3, 28029 Madrid, Spain. Electronic address: groncador@cnio.es., Sabattini E; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy. Electronic address: elena.sabattini@aosp.bo.it.
Jazyk: angličtina
Zdroj: Human pathology [Hum Pathol] 2022 Jun; Vol. 124, pp. 67-75. Date of Electronic Publication: 2022 Mar 23.
DOI: 10.1016/j.humpath.2022.03.008
Abstrakt: The differential diagnosis between lymphoplasmacytic lymphoma (LPL) and marginal zone B-cell lymphoma, particularly splenic type (SMZL), can be challenging on onset of bone marrow biopsy (BMB) since morphology and phenotype are not specific and clinical features can overlap or be mildly developed at diagnosis. The LPL-specific L265P mutation in the MYD88 gene is not available in all laboratories, and genetic aberrancies identified in SMZL (del7q, mutations of NOTCH2 and KLF2) are seldom searched in routine practice. The study aim is to investigate the potential role of myeloid nuclear differentiation antigen (MNDA) expression in this specific differential diagnosis. We report MNDA reactivity in 559 patients with small B-cell lymphoma including bone marrow biopsies from 90 LPL and 91 SMZL cases. MYD88 p.Leu265Pro mutation status was assessed and confirmed as positive in 24 of 90 LPL cases, which served as the test set. MNDA staining was negative in 23 of 24 LPL cases in the test set (96%). In the 157 remaining cases (66 LPL, 91 SMZL), which served as the validation set, the MYD88 p.Leu265Pro mutation was unavailable and MNDA was more frequently expressed in SMZL (p < 0.00001). In addition, immunohistochemical features more consistent with SMZL (i.e., presence of CD23+ follicular dendritic cell meshworks, polytypic plasma cells, DBA44 reactivity) were more often present in MNDA-positive cases (statistically significant for 2 such parameters). On the widest case series so far published focusing on LPL and SMZL immunohistochemical diagnosis at onset of BMB, we demonstrated that MNDA expression significantly support the diagnosis of SMZL. This observation may be of particular help in cases where the MYD88 p.Leu265Pro mutational status and/or SMZL-related genetic aberrations are unavailable.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: